HERSCHORN, S.; NAZIR, J.; RAMOS, B.; HAKIMI, Z. Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada. Canadian Urological Association Journal, [S. l.], v. 11, n. 3-4, p. 123–30, 2017. DOI: 10.5489/cuaj.4114. Disponível em: https://cuaj.ca/index.php/journal/article/view/4114. Acesso em: 1 may. 2024.